Form 4: Precigen COO Buys 2,000 Shares, Boosts Stake

Precigen's Chief Operating Officer, Rutul R. Shah, acquired 2,000 shares of common stock at $3.40 per share, increasing his beneficial ownership to 405,959 shares.

Summary

• Rutul R. Shah, Chief Operating Officer of Precigen, Inc. (PGEN), acquired 2,000 shares of common stock.
• The transaction occurred on September 26, 2025, at a price of $3.40 per share.
• Following this acquisition, Shah's direct beneficial ownership in Precigen, Inc. common stock increased to 405,959 shares.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The Chief Operating Officer's acquisition of additional shares indicates strong internal confidence in the company's current valuation and future prospects.

Positives

• Chief Operating Officer Rutul R. Shah increased his direct beneficial ownership by acquiring 2,000 shares of common stock.
• The acquisition at $3.40 per share demonstrates management's confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned purchase.

Negatives

• No negative information is disclosed in this Form 4 filing.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This filing does not provide forward-looking statements or guidance.

Management Comments

• This filing does not contain notable quotes or paraphrased statements from company management beyond the transaction details.

Industry Context

Insider purchases, such as this one by Precigen's COO, are often viewed by the market as a signal of management's belief in the company's intrinsic value and future performance, potentially indicating undervaluation or positive upcoming developments. This can be a positive indicator for investors, especially in the biotechnology sector where company-specific developments heavily influence stock performance.

Comparison to Industry Standards

• Insider buying activity is a common occurrence across all industries. While the specific amount of shares purchased by Precigen's COO is not directly comparable to specific projects or results of other companies, the act of an executive increasing their stake is generally interpreted as a vote of confidence.
• For example, similar insider purchases have been observed in other biotech companies like Moderna (MRNA) or BioNTech (BNTX) when executives believe in their pipeline or market position. The significance of this purchase should be viewed in the context of the executive's overall compensation and existing holdings.

Stakeholder Impact

• Shareholders: Potentially positive, as insider buying can boost investor confidence and signal a belief in future stock appreciation.
• Employees: May perceive increased stability and confidence from leadership.

Next Steps

• This filing does not mention any specific future actions, events, or milestones.

Key Dates

Recommendation

The Chief Operating Officer's decision to personally invest an additional amount in the company's common stock at $3.40 per share is a strong signal of management's conviction in Precigen's intrinsic value and future growth trajectory. This insider buying activity, especially from a high-ranking executive, often precedes positive developments or indicates a belief that the stock is currently undervalued, making it an attractive entry point for investors.

Keywords

Precigen, PGEN, insider trading, Form 4, stock acquisition, Rutul R. Shah, Chief Operating Officer, common stock, beneficial ownership, 10b5-1 plan